Despite advances in secondary prevention strategies in patients with cardiovascular
disease, the residual risk of recurrent atherothrombotic events remains high. Dual …

Introduction Certain low-molecular-weight heparins have been reported to reduce tumor
growth and metastasis in tumor cell-inoculated mouse models and cancer patients …

Background Central venous catheters are prone to clotting, particularly in patients with
cancer. Although low-molecular-weight heparin and direct oral anticoagulants, such as …

Pharmacological inhibition of factor Xa by rivaroxaban has been shown to mediate
cardioprotection and is frequently used in patients with, eg, atrial fibrillation. Rivaroxaban's …

The currently available oral anti-Xa agents are claimed to produce their anticoagulant and
antithrombotic effects solely by the inhibition of factor Xa. This study profiled various anti-Xa …

Functional tests for lupus anticoagulants (LA) as part of a thrombophilia workup are
commonly performed in patients under anticoagulant therapy that may interfere with assay …

Background A rapid test to detect apixaban treatment would be useful in acute situations
such as major bleeding, urgent surgery, or in acute thrombosis. Objective This article aims to …

The management of factor Xa (FXa) inhibitor-associated bleeding remains a clinical
challenge. Massive bleeding is often associated with complex coagulopathy and, thus, the …

Background At sites of vessel injury, thrombin acts as the central mediator of coagulation by
catalyzing fibrin clot formation and platelet activation. Thrombin generation is most …

Background Comparative pharmacokinetics and pharmacodynamics (PK/PD) of apixaban
and rivaroxaban have not been studied in dogs and the propensity of these drugs to cause …